• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

The World Market for Pulmonary Arterial Hypertension is Expected to Be Worth Over $2 Billion By 2014

Posted on: Thursday, 16 March 2006, 15:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c34378) has announced the addition of Stakeholder Perspectives: Pulmonary Arterial Hypertension - A Small Market Gets Big Attention to their offering.

We expect the global pulmonary arterial hypertension (PAH) market to grow from $636m in 2004 to just over $2 billion by 2014, as new product and formulation launches in the US and a healthy late-stage pipeline drive sales growth. With this increased interest, combined with increased awareness and R&D activity, treatment for this orphan disease is set to enter a new era.

Scope of this title:

-- Comprehensive analysis of the attractiveness of the PAH market based on epidemiology, unmet needs, R&D activity and potential revenue

-- Analysis of clinical trial data and market potential of the recently launched PAH specific therapies and compounds in late stage development

-- Detailed comparative analysis of all PAH specific compounds in terms of efficacy, drug delivery, target audience and cost

-- In-depth profiles of current treatments, including PAH specific and non-PAH specific compounds

Highlights of this title:

PAH is a rare condition with an estimated 146,000 sufferers across the US, EU and Japan. However, despite this low patient population, this market has attracted R&D investment due to the high unmet needs and high treatment values per patient.

Despite low patient numbers, it is estimated that up to 75% of these patients are not recognized and treated with therapy, creating significant room for growth in the number of patients treated with PAH therapies over the next decade.

Actelions Tracleer, the first oral therapy approved by the FDA in 2001, will come under significant competitive pressure over the next three years. With approval for Encysives Thelin expected in March 2006 and Myogens ambrisentan expected to launch in 2007, an intense marketing battle is expected as each company fights for market share.

Reasons to order your copy:

-- Assess the attractiveness of the PAH market for R&D investment and/or in-licensing activity

-- Gain insight into the current challenges and commercial opportunities associated with this devastating disease

-- Access key opinion leader views on the relative merits and weaknesses of current and future treatments for PAH, and the unmet needs therein

For more information visit http://www.researchandmarkets.com/reports/c34378

Source: Datamonitor

Source: Business Wire

More News in this Category